REVVITY INC(RVTY)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

RVTY REVVITY INC

休市中 06-12 16:00:00 EDT

99.66

-1.86

-1.83%

盘后99.66

+0.000.00%

19:12 EDT

最高103.60	最低98.42	成交量92.74万
今开102.34	昨收101.52	日振幅5.10%
总市值111.42亿	流通市值105.64亿	总股本1.12亿
成交额9,271万	换手率0.87%	流通股本1.06亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"RVTY","market":"US","secType":"STK","nameCN":"REVVITY INC","latestPrice":99.66,"timestamp":1781294400000,"preClose":101.52,"halted":0,"volume":927423,"hourTrading":{"tag":"盘后","latestPrice":99.66,"preClose":99.66,"latestTime":"19:12 EDT","volume":3509,"amount":349715.88,"timestamp":1781305973221,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.01832151300236406,"floatShares":106000000,"shares":111799374,"eps":2.094156,"marketStatus":"休市中","change":-1.86,"latestTime":"06-12 16:00:00 EDT","open":102.34,"high":103.6,"low":98.42,"amount":92707447.44365999,"amplitude":0.051024,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.094156,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":-141681600000,"exchange":"NYSE","adjPreClose":101.52,"dividendRate":0.00281,"preHourTrading":{"tag":"盘前","latestPrice":103.99,"preClose":101.415,"latestTime":"07:04 EDT","volume":2,"amount":207.98,"timestamp":1781262281075,"change":2.575,"changeRate":0.025391,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":99.66,"preClose":99.66,"latestTime":"19:12 EDT","volume":3509,"amount":349715.88,"timestamp":1781305973221,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7368922796308044,"impliedVol":0.359,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/RVTY/tweets","defaultTab":"tweets","newsList":[{"id":"1157892163","title":"REVVITY INC获FDA批准总睾酮测定试剂，提供全面自动化睾酮检测方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1157892163","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157892163?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:05","pubTimestamp":1778673929,"startTime":"0","endTime":"0","summary":"REVVITY INC宣布，其总睾酮测定试剂已获得美国食品药品监督管理局（FDA）的批准。这一进展使得该公司能够提供一套全面的自动化睾酮检测解决方案，旨在提升临床实验室的检测效率与准确性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4585","RVTY","BK4121","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148774755","title":"异动解读 | 第一季度利润超预期叠加战略业务调整，REVVITY INC盘中大涨6.24%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148774755","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148774755?lang=zh_cn&edition=full","pubTime":"2026-05-05 21:36","pubTimestamp":1777988207,"startTime":"0","endTime":"0","summary":"REVVITY INC今日盘中大涨6.24%，引起了市场的广泛关注。同时，公司宣布已决定剥离其中国免疫诊断业务，此举被分析师认为在战略上是正确的，预计将提升公司有机增长。尽管公司因剥离中国业务而下调了全年营收与利润指引，但市场更关注其核心业务的盈利能力和战略聚焦。公司预计业务将从第一季度到第二季度迎来季节性回升，且第三季度利润率有望攀升至约29%。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180703095","title":"Revvity高管称一季度至二季度将现季节性增长 预计三季度利润率将升至约29%——电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1180703095","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180703095?lang=zh_cn&edition=full","pubTime":"2026-05-05 20:33","pubTimestamp":1777984382,"startTime":"0","endTime":"0","summary":"在最新电话会议中，Revvity公司高管透露，从第一季度到第二季度，公司业务预计将迎来季节性回升。此外，管理层预计，第三季度的利润率有望攀升至约29%的水平。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4588","BK4121","BK4585","IE00BN0W2W23.USD","RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1107549957","title":"REVVITY INC高管透露：制药与学术客户贡献自2023年第二季度以来首次正向增长","url":"https://stock-news.laohu8.com/highlight/detail?id=1107549957","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1107549957?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:48","pubTimestamp":1777981736,"startTime":"0","endTime":"0","summary":"在最新电话会议中，REVVITY INC管理层指出，公司从制药领域及学术机构客户获得的业务出现显著回暖。这是自2023年第二季度以来，相关客户群体首次实现正向增长。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","IE00BN0W2T93.GBP","BK4588","BK4585","IE00BN0W2W23.USD","RVTY","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119437712","title":"Revvity高管称公司预计2026年前在华生命科学业务将持续甚至加速发展——电话会议","url":"https://stock-news.laohu8.com/highlight/detail?id=1119437712","media":"美股速递","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1119437712?lang=zh_cn&edition=full","pubTime":"2026-05-05 19:41","pubTimestamp":1777981277,"startTime":"0","endTime":"0","summary":"Revvity公司高管在电话会议中表示，预计直至2026年，其在中国市场的生命科学业务表现将保持延续态势，甚至有望实现进一步加速。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY","BK4588","IE00BN0W2T93.GBP","BK4121","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1130436153","title":"REVVITY INC签署意向书剥离中国免疫诊断业务 最终协议预计2026年第二季度达成","url":"https://stock-news.laohu8.com/highlight/detail?id=1130436153","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130436153?lang=zh_cn&edition=full","pubTime":"2026-05-05 18:03","pubTimestamp":1777975392,"startTime":"0","endTime":"0","summary":"REVVITY INC（股票代码：RVTY）近日宣布已就剥离其中国免疫诊断业务签署意向书。这项战略性举措标志着公司正优化其诊断业务组合，将资源集中于核心增长领域。\n根据公司披露的时间表，双方预计将在2026年第二季度完成最终协议的签署。该交易将遵循标准的监管审批程序，具体交易条款尚未对外披露。\n此次业务剥离符合REVVITY INC全球战略调整方向，旨在提升运营效率并强化市场竞争力。中国市场免疫诊断业务的剥离将为公司带来更灵活的资源调配空间，同时为相关业务寻找更专业的发展平台。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY","IE00BN0W2T93.GBP","BK4588","IE00BN0W2V16.EUR","BK4121","IE00BN0W2W23.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1183347107","title":"财报前瞻 ｜REVVITY INC本季度营收预计小幅增长，机构观点偏正面","url":"https://stock-news.laohu8.com/highlight/detail?id=1183347107","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183347107?lang=zh_cn&edition=full","pubTime":"2026-04-28 11:00","pubTimestamp":1777345233,"startTime":"0","endTime":"0","summary":"REVVITY INC将于2026年05月05日发布最新季度财报，市场聚焦营收恢复与盈利质量的边际变化及诊断与生命科学双主业的结构优化进展。市场一致预期显示，本季度REVVITY INC营收预计为7.03亿美元，同比增6.37%；调整后每股收益预计为1.02美元，同比增7.06%；EBIT预计为1.63亿美元，同比降2.74%。多家机构在最近六个月内对REVVITY INC的观点偏正面，主线为营收恢复与盈利质量稳中有进、诊断与生命科学结构均衡。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻 ｜REVVITY INC本季度营收预计小幅增长，机构观点偏正面","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2613245276","title":"Revvity, Inc.涨0.09% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2613245276","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613245276?lang=zh_cn&edition=full","pubTime":"2026-02-20 23:01","pubTimestamp":1771599683,"startTime":"0","endTime":"0","summary":"北京时间2026年02月20日23时01分，Revvity, Inc.股票出现波动，股价大幅拉升0.09%。Revvity, Inc.股票所在的生命科学行业中，整体跌幅为0.86%。其相关个股中，Ispecimen Inc.、Guardant Health, Inc.、Endra Life Sciences Inc.涨幅较大，Ispecimen Inc.、Grail, Inc.、Bioaffinity Technologies, Inc.较为活跃，换手率分别为71.38%、14.41%、2.52%，振幅较大的相关个股有Advanced Biomed Inc.、Ispecimen Inc.、燃石医学，振幅分别为17.50%、10.67%、10.39%。Revvity, Inc.公司简介：瑞孚迪是一家全球生命科学和诊断公司，成立于2023年，由珀金埃尔默更名而来。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022023012395418847&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026022023012395418847&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVTY","BK4588","IE00BN0W2T93.GBP","BK4121","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2609135519","title":"Revvity, Inc.涨0.58% 股价突破100美元大关","url":"https://stock-news.laohu8.com/highlight/detail?id=2609135519","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609135519?lang=zh_cn&edition=full","pubTime":"2026-02-06 22:34","pubTimestamp":1770388473,"startTime":"0","endTime":"0","summary":"北京时间2026年02月06日22时34分，Revvity, Inc.股票出现异动，股价大幅上涨0.58%。Revvity, Inc.股票所在的生命科学行业中，整体涨幅为0.16%。其相关个股中，Ispecimen Inc.、Inotiv, Inc.、Personalis, Inc.涨幅较大，Ispecimen Inc.、Xwell, Inc.、Bioaffinity Technologies, Inc.较为活跃，换手率分别为91.25%、0.54%、0.19%，振幅较大的相关个股有Xwell, Inc.、Ispecimen Inc.、Check-Cap Ltd.，振幅分别为10.42%、10.29%、5.66%。Revvity, Inc.公司简介：瑞孚迪是一家全球生命科学和诊断公司，成立于2023年，由珀金埃尔默更名而来。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020622343495402f9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2026020622343495402f9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVTY","BK4121","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131022622","title":"REVVITY高管表示制药生物技术领域持续呈现积极趋势，涵盖最惠国协议、生物技术融资及并购环境","url":"https://stock-news.laohu8.com/highlight/detail?id=1131022622","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1131022622?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:45","pubTimestamp":1770039956,"startTime":"0","endTime":"0","summary":"REVVITY公司高管指出，当前制药与生物技术行业持续显现积极发展态势。这一趋势主要体现在最惠国待遇协议（MFN）的推进、生物技术领域融资活动的活跃以及并购市场环境的改善等多个维度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","BK4588","RVTY","BK4585","IE00BN0W2T93.GBP","BK4121","IE00BN0W2V16.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112221094","title":"REVVITY高管透露成本效益措施预计将于2026年第二季度末全面落地","url":"https://stock-news.laohu8.com/highlight/detail?id=1112221094","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112221094?lang=zh_cn&edition=full","pubTime":"2026-02-02 21:35","pubTimestamp":1770039316,"startTime":"0","endTime":"0","summary":"REVVITY公司管理层近日透露，公司推行的成本优化方案预计将在2026年第二季度末前全面实施。该举措旨在通过系统性效率提升强化企业财务韧性，为长期战略布局提供支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","BK4585","RVTY","BK4121","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106908475","title":"REVVITY INC股价飙升至逾九个月高点，公司宣布将超越2025年盈利预测区间，尾盘大涨9.1%","url":"https://stock-news.laohu8.com/highlight/detail?id=1106908475","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1106908475?lang=zh_cn&edition=full","pubTime":"2026-01-13 22:39","pubTimestamp":1768315161,"startTime":"0","endTime":"0","summary":"REVVITY INC股价强势突破九个月高位，此前该公司发布声明称其2025财年盈利表现将超出市场预期区间。这一利好消息推动股价盘中持续走强，最终录得9.1%的显著涨幅，展现出市场对该公司未来业绩的强烈信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4121","BK4585","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","RVTY","BK4588","IE00BN0W2T93.GBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1180282614","title":"REVVITY INC携手礼来 通过Xynthetica平台为生物技术公司提供预测模型访问资金","url":"https://stock-news.laohu8.com/highlight/detail?id=1180282614","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1180282614?lang=zh_cn&edition=full","pubTime":"2026-01-09 21:02","pubTimestamp":1767963741,"startTime":"0","endTime":"0","summary":"REVVITY INC宣布启动创新合作计划，该计划将专项资助参与合作的生物技术企业，使其能够通过REVVITY Signals的Xynthetica服务平台，直接获取制药巨头礼来公司开发的先进预测模型。\n这项合作旨在加速生物技术领域的研发进程，通过资金支持降低创新门槛。参与企业将获得技术准入资格，利用礼来经过验证的预测模型优化药物发现流程。REVVITY Signals的Xynthetica平台作为技术枢纽，将为模型部署和应用提供全流程支持。\n此次合作凸显了行业领先企业共同推动生物医药创新的承诺。通过资源共享与协同创新，有望为患者带来更高效的疗法，同时为参与方创造新的增长机遇。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"51e6d18501975df584fd73dcbb421a75","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0354030438.USD","LU1551013425.SGD","GB00BDT5M118.USD","LU2324357040.USD","LU2361044949.HKD","LU0198837287.USD","RVTY","SG9999015952.SGD","LU2237443549.SGD","LU0820561909.HKD","LU0708995401.HKD","IE00BFSS8Q28.SGD","LU2602419157.SGD","BK4534","LU2264538146.SGD","LU2491050071.SGD","LU1093756325.SGD","IE00B4R5TH58.HKD","BK4581","LU1323610961.USD","LU0320765992.SGD","LU1093756168.USD","LU2237443622.USD","LU2360106947.USD","SG9999015945.SGD","LU1623119135.USD","LU1814569148.SGD","IE0005OL40V9.USD","IE00BJJMRZ35.SGD","LU0106261372.USD","LU1291159041.SGD","LU2746668974.SGD","SG9999014906.USD","LU2108987350.USD","IE0004445015.USD","LU1035775433.USD","LU2471134523.USD","IE0002141913.USD","LU1280957306.USD","LU0109391861.USD","SGXZ99366536.SGD","LU1127390331.HKD","IE0009355771.USD","LU1551013342.USD","SG9999015986.USD","SG9999015978.USD","LU2168564222.USD","LU0432979614.USD","LU1720051017.SGD","LU0079474960.USD","SG9999001176.SGD","BK4588","LU2168564149.EUR","LU0683600562.USD","LU0097036916.USD","LU2750360641.GBP","SG9999018865.SGD","IE00BN0W2T93.GBP","IE00BWXC8680.SGD","BK4121","LU0456855351.SGD","LU2106854487.HKD","LU0109394709.USD","LU1868836591.USD","LU0689472784.USD","LU1868836914.USD","LU2746668461.USD","LU0061475181.USD","LU2471134879.HKD","BK4585","IE00BJJMRY28.SGD","LU0122379950.USD","LU2112291526.USD","LU2361045086.USD","IE00BK4W5M84.HKD","LU0234572021.USD","LU2456880835.USD","LU0266013472.USD","LU0094547139.USD","SGXZ31699556.SGD","LU0256863811.USD","LU1989771016.USD","LU0823416689.USD","IE00BJJMRX11.SGD","LU0786609619.USD","LU2237443895.HKD","LU2168564495.EUR","LU1983299246.USD","LU2237443382.USD","LU0353189680.USD","LLY","LU1061106388.HKD","LU0006306889.USD","SGXZ51526630.SGD","LU0114720955.EUR","BK4007","IE00B775H168.HKD","LU0203201768.USD","IE00BFTCPJ56.SGD","LU0385154629.USD","LU1057294990.SGD","IE00B4JS1V06.HKD","SGXZ81514606.USD","LU0320765059.SGD","LU0238689110.USD","LU2211815571.USD","LU0823434740.USD","IE00BN0W2V16.EUR","LU0820561818.USD","LU0882574055.USD","IE00B1XK9C88.USD","LU0672654240.SGD","LU0203202063.USD","LU1712237335.SGD","SG9999014880.SGD","SGXZ57979304.SGD","SG9999014914.USD","LU2491049909.HKD","LU2237443465.HKD","SG9999001176.USD","LU0943347566.SGD","LU0289739699.SGD","LU1868836757.USD","LU0225283273.USD","LU0640476718.USD","LU0882574139.USD","LU0823434583.USD","BK4533","LU2089984988.USD","IE00BKDWB100.SGD","LU1366192091.USD","LU2471134796.USD","LU1232071149.USD","LU2087625088.SGD","LU2461242641.AUD","IE00BK4W5L77.USD","LU1720051108.HKD","LU0471298777.SGD","IE00BJLML261.HKD","LU1974910355.USD","LU2237443978.SGD","SG9999018857.SGD","LU2168564065.EUR","LU0096364046.USD","LU2023250504.SGD","LU0354030511.USD","LU2471134952.CNY","IE00BKPKM429.USD","LU2357305700.SGD","LU2552382058.USD","LU0889565916.HKD","LU0471298694.HKD","IE00B1BXHZ80.USD","IE00BJT1NW94.SGD","IE00BN29S564.USD","BK4516","SG9999014898.SGD","LU2265009873.SGD","LU1069344957.HKD","LU2750360997.AUD","LU1988902786.USD","LU0353189763.USD","LU1868837300.USD","LU1868837136.USD","LU1804176565.USD","LU0256863902.USD","BK4599","SG9999013999.USD","LU1917777945.USD","LU0323591593.USD","LU2417539215.USD","IE0004445239.USD","IE00B2B36J28.USD","LU0058720904.USD","LU1064131342.USD","LU0316494557.USD","LU2468319806.SGD","LU0417517546.SGD","LU2552382215.SGD","LU2236285917.USD","LU2361044865.SGD","LU2237438978.USD","LU1023059063.AUD","LU2462157665.USD","LU2491050154.USD","LU2063271972.USD","LU0466842654.USD","SG9999017495.SGD","LU2168563687.JPY","LU2552382132.HKD","LU1548497426.USD","LU0787776722.HKD","LU1267930730.SGD","IE00BFSS7M15.SGD","IE00B7KXQ091.USD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149633213","title":"REVVITY INC：Bofa Global Research将评级从“买入”下调至“中性”，目标价上调至110美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1149633213","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1149633213?lang=zh_cn&edition=full","pubTime":"2025-12-15 20:11","pubTimestamp":1765800671,"startTime":"0","endTime":"0","summary":"REVVITY INC：Bofa Global Research将评级从“买入”下调至“中性”，并将目标价从105美元上调至110美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY","IE00BN0W2T93.GBP","IE00BN0W2V16.EUR","BK4588","BK4121","BK4585","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508800145","title":"Keybanc：维持Revvity(RVTY.US)评级，由增持调整至增持评级, 目标价由132.00美元调整至145.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2508800145","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508800145?lang=zh_cn&edition=full","pubTime":"2025-02-03 21:51","pubTimestamp":1738590713,"startTime":"0","endTime":"0","summary":"Keybanc：维持Revvity(RVTY.US)评级，由增持调整至增持评级, 目标价由132.00美元调整至145.00美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/03215147941462.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2508748131","title":"Revvity, Inc.2024财年实现净利润2.83亿美元，同比增加57.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508748131","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508748131?lang=zh_cn&edition=full","pubTime":"2025-02-03 00:00","pubTimestamp":1738512034,"startTime":"0","endTime":"0","summary":"2月3日，Revvity, Inc.公布财报，公告显示公司2024财年净利润为2.83亿美元，同比增加57.22%；其中营业收入为27.55亿美元，同比增加0.15%，每股基本收益为--。从资产负债表来看，Revvity, Inc.总负债47.26亿美元，其中短期债务242000.00美元，资产负债比为2.63，流动比率为3.60。机构评级：截至2025年2月3日，当前有17家机构对Revvity, Inc.目标价做出预测，其中目标均价为134.41美元，其中最低目标价为102.00美元，最高目标价为155.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203000037abc01292&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250203000037abc01292&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114824764","title":"异动解读 | Revvity 2024年Q4财报佳绩 盘前大涨6.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1114824764","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1114824764?lang=zh_cn&edition=full","pubTime":"2025-01-31 21:02","pubTimestamp":1738328545,"startTime":"0","endTime":"0","summary":"今日盘前,Revvity Inc. (NYSE:RVTY)股价大涨6.03%,报收33.85美元。大涨的主要原因是公司公布的2024年第四季度财报超出市场预期。\n\nRevvity公司在财报中公布,2024年第四季度调整后每股收益1.42美元,高于分析师预期的1.37美元,同比增长13.6%;季度销售额达到7.29亿美元,也略高于预期的7.28亿美元,同比增长4.81%。优异的财报数据一定程度上反映了公司良好的发展态势和盈利能力。\n\n财报公布后,投资者对Revvity的未来增长前景抱有较高期待,从而推动了股价的大幅上涨。但需要关注的是,公司能否在未来持续保持高速增长,仍有待进一步观察。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1142694126","title":"Revvity 2024年第四季度调整后每股收益 $1.42 超过预期 $1.37，销售额 $7.29372亿 超过预期 $7.28043亿","url":"https://stock-news.laohu8.com/highlight/detail?id=1142694126","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1142694126?lang=zh_cn&edition=full","pubTime":"2025-01-31 19:04","pubTimestamp":1738321457,"startTime":"0","endTime":"0","summary":"与去年同期的每股收益 $1.25 相比，这一数字增长了13.6%。公司报告季度销售额为 $7.29372亿，超过分析师普遍预期的 $7.28043亿，增长了0.18%。以上内容来自Benzinga Earnings专栏，原文如下：Revvity  reported quarterly earnings of $1.42 per share which beat the analyst consensus estimate of $1.37 by 3.65 percent. This is a 13.6 percent increase over earnings of $1.25 per share from the same period last year.  The company reported quarterly sales of $729.372 million which beat the analyst consensus estimate of $728.043 million by 0.18 percent.  This is a 4.81 percent inc","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Revvity 2024年第四季度调整后每股收益 $1.42 超过预期 $1.37，销售额 $7.29372亿 超过预期 $7.28043亿","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RVTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2503058551","title":"Revvity, Inc.盘中异动 早盘股价大涨5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2503058551","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2503058551?lang=zh_cn&edition=full","pubTime":"2025-01-13 22:46","pubTimestamp":1736779600,"startTime":"0","endTime":"0","summary":"北京时间2025年01月13日22时46分，Revvity, Inc.股票出现异动，股价快速拉升5.08%。Revvity, Inc.股票所在的生命科学行业中，整体涨幅为1.77%。Revvity, Inc.公司简介：Revvity 为制药、生物医学、化学、环境和一般工业市场提供仪器、测试、服务和软件解决方案。Revvity 提供产品和服务，其范围从基因筛选和环境分析工具到信息学和企业软件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113224640aba93528&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250113224640aba93528&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4121","RVTY","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2483581323","title":"Revvity, Inc.盘中异动 股价大跌5.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483581323","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483581323?lang=zh_cn&edition=full","pubTime":"2024-11-16 03:16","pubTimestamp":1731698174,"startTime":"0","endTime":"0","summary":"北京时间2024年11月16日03时16分，Revvity, Inc.股票出现波动，股价快速下挫5.04%。Revvity, Inc.股票所在的生命科学行业中，整体跌幅为3.87%。Revvity, Inc.公司简介：Revvity 为制药、生物医学、化学、环境和一般工业市场提供仪器、测试、服务和软件解决方案。Revvity 提供产品和服务，其范围从基因筛选和环境分析工具到信息学和企业软件。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116031614a23bdf33&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241116031614a23bdf33&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4585","BK4588","RVTY","BK4121"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.revvity.com","stockEarnings":[{"period":"1week","weight":0.0131},{"period":"1month","weight":0.0489},{"period":"3month","weight":0.1647},{"period":"6month","weight":-0.0083},{"period":"1year","weight":0.0414},{"period":"ytd","weight":0.0301}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Revvity, Inc.在1947年于马萨诸塞州成立。该公司是健康科学解决方案、技术、专业知识和服务的领先供应商，提供从发现到开发、从诊断到治愈的完整工作流程。Revvity正在彻底改变医疗保健领域的可能性，在转化多组学技术、生物标志物识别、成像、预测、筛查、检测和诊断、信息学等方面拥有专门的重点领域。","yearOnYearQuotes":[{"month":1,"riseRate":0.565217,"avgChangeRate":0.028629},{"month":2,"riseRate":0.630435,"avgChangeRate":0.005389},{"month":3,"riseRate":0.434783,"avgChangeRate":-0.009865},{"month":4,"riseRate":0.446809,"avgChangeRate":-0.003599},{"month":5,"riseRate":0.659574,"avgChangeRate":0.025792},{"month":6,"riseRate":0.404255,"avgChangeRate":0.003716},{"month":7,"riseRate":0.565217,"avgChangeRate":0.007009},{"month":8,"riseRate":0.521739,"avgChangeRate":0.006531},{"month":9,"riseRate":0.456522,"avgChangeRate":0.000154},{"month":10,"riseRate":0.586957,"avgChangeRate":0.014619},{"month":11,"riseRate":0.673913,"avgChangeRate":0.025718},{"month":12,"riseRate":0.586957,"avgChangeRate":0.022842}],"exchange":"NYSE","name":"REVVITY INC","nameEN":"REVVITY INC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"REVVITY INC(RVTY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供REVVITY INC(RVTY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"REVVITY INC,RVTY,REVVITY INC股票,REVVITY INC股票老虎,REVVITY INC股票老虎国际,REVVITY INC行情,REVVITY INC股票行情,REVVITY INC股价,REVVITY INC股市,REVVITY INC股票价格,REVVITY INC股票交易,REVVITY INC股票购买,REVVITY INC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"REVVITY INC(RVTY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供REVVITY INC(RVTY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}